Business Wire

CA-ENCHROMA

16.7.2024 13:01:33 CEST | Business Wire | Press release

Share
EnChroma Announces Organizations Can Now Join International Color Blindness Awareness Month™ 2024

EnChroma® — creators of glasses for color blindness — today announced that organizations and businesses can now sign up to support International Color Blindness Awareness Month™ 2024. Every September, hundreds of organizations come together to promote ‘color accessibility’ and inclusion for the one in 12 men (8%) and one in 200 women (.5%) who are color blind; an estimated 13 million in the United States; 30 million in Europe; and 350 million worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716891549/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Depiction of red-green color blind and normal color vision views of colorful buildings in Amsterdam. (Photo: Business Wire)

Anytime in September, hundreds of museums, universities, businesses, libraries, schools, park systems, tourism agencies, philanthropic groups and others will make social media posts, disseminate information, and engage in other activities to educate the public about the prevalence and effects of Color Vision Deficiency (CVD).

“Awareness of just how common color blindness is and how significant its impacts are, still remains low amongst employers, educators, parents and the general public,” said Erik Ritchie, CEO of EnChroma. “From color confusion in the workplace, at school, when enjoying sports and the outdoors, or when simply doing daily activities can be frustrating for those with CVD. This year, we hope even more organizations will support International Color Blindness Awareness Month to both educate and advocate on behalf of the color blind.”

While people with normal color vision see over one million shades of color, the red-green color blind only see an estimated 10% of hues and shades. As a result, colors can appear dull, indistinct and difficult to discern; red can appear brown; green can look tan, gray or yellow; and purple and blue look similar.

Click here to see more images depicting color blindness.

Last year, over 250 organizations around the world used their voices and platforms in support including multinational corporations such as Honeywell Aerospace, Siemens Energy and Faber-Castell; renowned museums such as the Centre Pompidou and the Georgia O’Keeffe Museum; universities such as the University of North Carolina, Boston University and North Carolina State University; state and national parks such as Friends of Kauai Wildlife Refuges and Alaska State Parks; the Atlanta Botanical Garden; nature advocates like the Audubon Nature Institute; and groups such as Travel Oregon, Lions and Kiwanis clubs, and the Boy Scouts of America.

How to Apply

Organizations and businesses can sign up here to commit to making at least one social media post, or undertake any other activity, that promotes color blindness awareness in September, using any of an array of customizable images and templates. Do as little as make one social media post using a customizable template or create your own post(s) with easy-to-use tools. Participating organizations can choose to receive two pairs of EnChroma glasses to give away to color blind students, customers, staff or visitors. The offer to give away EnChroma glasses is not available to individuals.

EnChroma Color Accessibility Program™

EnChroma is the lead advocate for ‘color accessibility,’ helping more than 400 universities, K-12 schools, state and national parks, libraries, museums, tourism departments, attractions and other organizations purchase and loan EnChroma glasses to color blind students and guests. EnChroma donates a pair of glasses for each pair an organization buys to lend to the public or students. The program is also open to employers. Scenic viewers adapted for the color blind are also available and in use by park systems across 25 states.

EnChroma glasses are engineered with special optical filters that help the red-green color blind experience an expanded range of colors more vibrantly and distinctly to make schoolwork that involves color, art, nature and other experiences more ‘color accessible.’ The glasses do not deliver full color vision and results and reaction times vary. EnChroma glasses enhance color for approximately 80% of people with deuteranomalous or protanomalous red-green color blindness who have all three of their color sensing cones. Read this study by UC Davis about the glasses.

About EnChroma

Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for red-green color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with red-green color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Call 510-497-0048 or visit enchroma.com for more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716891549/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye